KLI

Real-world effectiveness and safety of adalimumab in Korean patients with intestinal Behcet's disease: a Korean Association for the Study of Intestinal Diseases (KASID) multicenter study

Metadata Downloads
Abstract
Background/aims: The short- and long-term effects of adalimumab (ADA) on Korean patients with intestinal Behcet's disease (BD) for remain unclear. Therefore, a multicenter study was performed to evaluate the efficacy and safety of ADA in Korean patients with intestinal BD in a real-world setting.

Methods: The medical records of 67 patients with BD prescribed ADA between January 2012 and December 2020 at five referral centers in Korea were retrospectively analyzed and the safety and efficacy of ADA within 52 weeks were assessed. To evaluate the clinical efficacy of ADA, the Disease Activity Index for Intestinal BD (DAIBD) and representative blood biochemical markers were compared at 0, 12, 24, and 52 weeks of ADA treatment.

Results: During the follow-up period of 52 weeks, 46 patients continued ADA treatment. The cumulative drug survival rate was 83.5%. The DAIBD score decreased over the study period (p < 0.001). Moreover, the erythrocyte sedimentation rate, serum C-reactive protein levels, and serum albumin levels significantly improved at 12, 24, and 52 weeks of ADA treatment (all, p <0.05).

Conclusion: As ADA is effective for refractory intestinal BD with few safety concerns in real-world situations, it is a potential treatment option for Korean patients with intestinal BD.
Author(s)
Seung Bum LeeHee Seung HongChang Kyun LeeBo-In LeeSol KimSeong-Joon KohHosun YuJung-Bin ParkSung Wook HwangByong Duk YeSuk-Kyun YangSang Hyoung Park
Issued Date
2023
Type
Article
Keyword
AdalimumabBehcet syndromeTreatment outcome
DOI
10.3904/kjim.2022.394
URI
https://oak.ulsan.ac.kr/handle/2021.oak/17164
Publisher
Korean Journal of Internal Medicine
Language
영어
ISSN
1226-3303
Citation Volume
38
Citation Number
5
Citation Start Page
661
Citation End Page
671
Appears in Collections:
Medicine > Nursing
공개 및 라이선스
  • 공개 구분공개
파일 목록
  • 관련 파일이 존재하지 않습니다.

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.